Home NDC 63539-031 Talzenna
Product NDC 63539-031
11-digit product format 635390031
Labeler code 63539
Product ID 63539-031_b653221e-971f-4452-92d4-797924f1ff59
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name talazoparib
Dosage form CAPSULE, LIQUID FILLED
Route ORAL
Labeler U.S. Pharmaceuticals
Application NDA217439
Marketing category NDA
Marketing start 2024-07-09
Substance TALAZOPARIB TOSYLATE
Active strength 1 mg/1
Pharmacologic classes Poly(ADP-Ribose) Polymerase Inhibitor [EPC], Poly(ADP-Ribose) Polymerase Inhibitors [MoA]
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 1 .
Orange Book products# Current product rows page 1 of 1 · 6 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N217439-001 TALZENNA TALAZOPARIB TOSYLATE EQ 0.1MG BASE CAPSULE / ORAL RLD 2024-03-07 N217439-002 TALZENNA TALAZOPARIB TOSYLATE EQ 0.25MG BASE CAPSULE / ORAL RLD 2024-03-07 N217439-003 TALZENNA TALAZOPARIB TOSYLATE EQ 0.35MG BASE CAPSULE / ORAL RLD 2024-03-07 N217439-004 TALZENNA TALAZOPARIB TOSYLATE EQ 0.5MG BASE CAPSULE / ORAL RLD 2024-03-07 N217439-005 TALZENNA TALAZOPARIB TOSYLATE EQ 0.75MG BASE CAPSULE / ORAL RLD 2024-03-07 N217439-006 TALZENNA TALAZOPARIB TOSYLATE EQ 1MG BASE CAPSULE / ORAL RLD, RS 2024-03-07
Orange Book patents# Current patent rows page 1 of 1 · 36 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N217439-001 10780088 2029-07-27 U-3651 2024-04-05 N217439-001 8012976 2029-07-27 Drug substance, Drug product 2024-04-05 N217439-001 8420650 2029-07-27 Drug substance, Drug product 2024-04-05 N217439-001 9820985 2029-07-27 U-2437 2024-04-05 N217439-001 10189837 2031-10-20 Drug substance, Drug product 2024-04-05 N217439-001 8735392 2031-10-20 Drug substance, Drug product 2024-04-05 N217439-002 10780088 2029-07-27 U-3651 2024-04-05 N217439-002 8012976 2029-07-27 Drug substance, Drug product 2024-04-05 N217439-002 8420650 2029-07-27 Drug substance, Drug product 2024-04-05 N217439-002 9820985 2029-07-27 U-2437 2024-04-05 N217439-002 10189837 2031-10-20 Drug substance, Drug product 2024-04-05 N217439-002 8735392 2031-10-20 Drug substance, Drug product 2024-04-05 N217439-003 10780088 2029-07-27 U-3651 2024-04-05 N217439-003 8012976 2029-07-27 Drug substance, Drug product 2024-04-05 N217439-003 8420650 2029-07-27 Drug substance, Drug product 2024-04-05 N217439-003 9820985 2029-07-27 U-2437 2024-04-05 N217439-003 10189837 2031-10-20 Drug substance, Drug product 2024-04-05 N217439-003 8735392 2031-10-20 Drug substance, Drug product 2024-04-05 N217439-004 10780088 2029-07-27 U-3651 2024-04-05 N217439-004 8012976 2029-07-27 Drug substance, Drug product 2024-04-05 N217439-004 8420650 2029-07-27 Drug substance, Drug product 2024-04-05 N217439-004 9820985 2029-07-27 U-2437 2024-04-05 N217439-004 10189837 2031-10-20 Drug substance, Drug product 2024-04-05 N217439-004 8735392 2031-10-20 Drug substance, Drug product 2024-04-05 N217439-005 10780088 2029-07-27 U-3651 2024-04-05 N217439-005 8012976 2029-07-27 Drug substance, Drug product 2024-04-05 N217439-005 8420650 2029-07-27 Drug substance, Drug product 2024-04-05 N217439-005 9820985 2029-07-27 U-2437 2024-04-05 N217439-005 10189837 2031-10-20 Drug substance, Drug product 2024-04-05 N217439-005 8735392 2031-10-20 Drug substance, Drug product 2024-04-05 N217439-006 10780088 2029-07-27 U-3651 2024-04-05 N217439-006 8012976 2029-07-27 Drug substance, Drug product 2024-04-05 N217439-006 8420650 2029-07-27 Drug substance, Drug product 2024-04-05 N217439-006 9820985 2029-07-27 U-2437 2024-04-05 N217439-006 10189837 2031-10-20 Drug substance, Drug product 2024-04-05 N217439-006 8735392 2031-10-20 Drug substance, Drug product 2024-04-05
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 3 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N217439-001 I-920 2026-06-20 N217439-002 I-920 2026-06-20 N217439-004 I-920 2026-06-20
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-08-01 22:54:32 2026-06 N217439-001 TALZENNA EQ 0.1MG BASE CAPSULE / ORAL RLD 2024-03-07 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-002 TALZENNA EQ 0.25MG BASE CAPSULE / ORAL RLD 2024-03-07 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-003 TALZENNA EQ 0.35MG BASE CAPSULE / ORAL RLD 2024-03-07 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-004 TALZENNA EQ 0.5MG BASE CAPSULE / ORAL RLD 2024-03-07 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-005 TALZENNA EQ 0.75MG BASE CAPSULE / ORAL RLD 2024-03-07 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-006 TALZENNA EQ 1MG BASE CAPSULE / ORAL RLD, RS 2024-03-07 a50c72e98297…
Observed Orange Book patent history# Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-08-01 22:54:32 2026-06 N217439-001 10780088 2029-07-27 U-3651 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-001 8012976 2029-07-27 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-001 8420650 2029-07-27 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-001 9820985 2029-07-27 U-2437 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-001 10189837 2031-10-20 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-001 8735392 2031-10-20 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-002 10780088 2029-07-27 U-3651 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-002 8012976 2029-07-27 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-002 8420650 2029-07-27 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-002 9820985 2029-07-27 U-2437 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-002 10189837 2031-10-20 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-002 8735392 2031-10-20 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-003 10780088 2029-07-27 U-3651 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-003 8012976 2029-07-27 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-003 8420650 2029-07-27 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-003 9820985 2029-07-27 U-2437 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-003 10189837 2031-10-20 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-003 8735392 2031-10-20 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-004 10780088 2029-07-27 U-3651 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-004 8012976 2029-07-27 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-004 8420650 2029-07-27 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-004 9820985 2029-07-27 U-2437 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-004 10189837 2031-10-20 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-004 8735392 2031-10-20 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-005 10780088 2029-07-27 U-3651 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-005 8012976 2029-07-27 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-005 8420650 2029-07-27 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-005 9820985 2029-07-27 U-2437 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-005 10189837 2031-10-20 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-005 8735392 2031-10-20 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-006 10780088 2029-07-27 U-3651 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-006 8012976 2029-07-27 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-006 8420650 2029-07-27 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-006 9820985 2029-07-27 U-2437 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-006 10189837 2031-10-20 Drug substance, Drug product 2024-04-05 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-006 8735392 2031-10-20 Drug substance, Drug product 2024-04-05 a50c72e98297…
Observed Orange Book exclusivity history# Captured, Edition, Application-product table Captured Edition Application-product Exclusivity code Expiration Source SHA-256 2026-08-01 22:54:32 2026-06 N217439-001 I-920 2026-06-20 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-002 I-920 2026-06-20 a50c72e98297…2026-08-01 22:54:32 2026-06 N217439-004 I-920 2026-06-20 a50c72e98297…
openFDA label cross-check# Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
Matched openFDA labels page 1 of 1 · 2 matching rows.
Additional Listing Data#
Finished product Yes
Brand name base Talzenna
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength TALAZOPARIB TOSYLATE 1 mg/1
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 1 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 02WK9U5NZC Internal UNII lookup
Harmonized RxCUI identifiers# RxCUI identifiers page 1 of 1 · 4 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 2099954 Internal RxNorm lookup 2099956 Internal RxNorm lookup 2591510 Internal RxNorm lookup 2591512 Internal RxNorm lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 63539-031-30 Talzenna 30 in 1 BOTTLE CAPSULE, LIQUID FILLED 30 1
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Marketing start Sample Exclude flag Status 63539-031-30 63539003130 30 CAPSULE, LIQUID FILLED in 1 BOTTLE (63539-031-30) 2024-07-09 No No Current